Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: an open-label, three-arm, randomized controlled phase II trial
Document Type
Journal Article
Publication Date
5-2016
Journal
Journal of Clinical Oncology
Volume
34
Issue
13
Inclusive Pages
1500-1509
DOI
10.1200/JCO.2015.65.0218
APA Citation
Petrylak, D., Tagawa, S., Kohli, M., Eisen, A., Canil, C., Aragon-Ching, J. B., & +16 additional authors (2016). Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: an open-label, three-arm, randomized controlled phase II trial. Journal of Clinical Oncology, 34 (13). http://dx.doi.org/10.1200/JCO.2015.65.0218
Peer Reviewed
1